COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits
Open Access
- 1 November 2020
- journal article
- review article
- Published by AACN Publishing in American Journal of Critical Care
- Vol. 29 (6), 489-492
- https://doi.org/10.4037/ajcc2020694
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During PandemicsJAMA, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- The epidemiology, diagnosis and treatment of COVID-19International Journal of Antimicrobial Agents, 2020
- Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping reviewInfectious Diseases of Poverty, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19Journal of Critical Care, 2020
- Clinical characteristics of hospitalized patients with SARS‐CoV‐2 infection: A single arm meta‐analysisJournal of Medical Virology, 2020
- Guide to Understanding the 2019 Novel CoronavirusMayo Clinic Proceedings, 2020
- Pathogenicity and transmissibility of 2019-nCoV—A quick overview and comparison with other emerging virusesMicrobes and Infection, 2020
- Choosing the Best Evidence to Guide Clinical Practice: Application of AACN Levels of EvidenceCritical Care Nurse, 2014